Time To Take Profits In XLV?
The healthcare fund just printed a record high, but cashing out of a steady compounder is often the wrong move.
A new high always feels like a moment of decision. For holders of the State Street Health Care Select Sector SPDR ETF (XLV), that moment is now. The fund just closed at $167.26, its highest level ever, after a +16.6% run over the past three months. When you see a gain like that, the natural question is whether to hold on, trim your stake, or get out entirely. XLV is an exchange-traded fund designed to give you a slice of the healthcare industry within the S&P 500, holding everything from pharmaceuticals to medical equipment companies.
How Solid Is This New Peak?
Before you act, it is worth looking at what drove this high. First, this is a concentrated fund. Its holdings sit “almost entirely in one sector, Health Care,” making it a single-industry allocation. The recent advance was also driven by a few key names. While participation was wide, with 24 of the 30 largest holdings rising over the past three months, the actual heavy lifting was done by a few. The “three biggest movers accounted for about 56% of the up-and-down price movement” among those top 30 holdings. On top of that, the basket is not cheap by its own historical standards. The fund’s holdings now trade at about 31.0 times earnings, compared to a roughly 5-year median of 26.8 for this fund.
So, What Should A Holder Do Now?
With the fund looking stretched and trading at a richer valuation, the temptation to sell is real. But for a long-term investor, the most sensible action is often the hardest one: do nothing. A new high, by itself, is not a signal to sell a quality asset. It is what you want your investments to do. This is compounding at work. Selling a fund that holds 63 positions across a vital sector just because it’s performing well can be a classic mistake, forcing you to pay taxes and find a new home for your capital. The price of earning long-term returns includes weathering volatility. The fund’s deepest fall in recent years was 17.1%, a figure that provides context for what a significant pullback could look like.
The fund currently sits about 10.3% above its 200-day moving average, which confirms it has run ahead of its trend. The only strong reason to act may have nothing to do with the market and everything to do with your own plan. If this strong performance has made your XLV position significantly larger than its target weight in your portfolio, trimming it back into line is simply disciplined rebalancing. This question of what to do at a new high is not unique to healthcare; other sectors like financials are facing similar moments.
Is There A Stronger ETF To Own Instead?
Whether you are inclined to keep holding or tempted to take the gain and look elsewhere, the same question follows: is there simply a better ETF to own right now? A new high tells you the price is up, not whether XLV still stacks up against its peers on valuation, return, and risk.
Our ETF Valuation and Performance Scorecard ranks the major ETFs side by side on exactly those measures, so you can see at a glance whether XLV is still near the top of the pack or whether your money could work harder somewhere else.
A Fund Is Only Part Of Your Portfolio, Check The Rest
A fund is just one piece of what you own, and the same scrutiny applies to every other position in your portfolio. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.